IPM Take
Cardiology has spent years talking about precision medicine. Kardigan is now putting several versions of that idea into expensive clinical trials.
Its clearest test is danicamtiv, an oral cardiac myosin activator being developed for dilated cardiomyopathy associated with MYH7 and TTN variants. In an earlier 41-patient, open-label Phase II study, left ventricular ejection fraction increased by 8.8 percentage points in the MYH7 cohort and 5.9 points in the TTN cohort, compared with 4.4 points in patients with other causes of DCM, where the confidence interval crossed zero. The study was small, uncontrolled and exploratory, so it cannot prove that genetic selection creates a superior treatment effect. But it provides exactly the kind of signal precision cardiology is supposed to test prospectively.
Kardigan is now doing that in the adaptive KINSHIP-DCM programme. Enrollment of the MYH7/TTN Phase IIb cohort was completed in July, the Phase III portion is underway, and Phase IIb topline data are expected in the first half of 2027.
The political and reimbursement question comes next. If genetic testing identifies a subgroup that benefits more, then genetic diagnosis stops being an academic refinement and becomes part of the treatment pathway. That would force payers to think about reimbursement for the test, not only the drug.
Precision medicine is easy to celebrate when it means better science. It becomes harder when health systems have to pay for the infrastructure that makes the science usable.
Executive Summary
Kardigan entered the second half of 2026 with $660.7 million in cash, cash equivalents and investments, following an IPO that generated $460 million in gross proceeds. The company says that funding is intended to advance its three lead programmes through key clinical readouts and support initiation of Phase III development.
Danicamtiv is a selective cardiac myosin activator being developed in genetic dilated cardiomyopathy. An earlier Phase IIa study enrolled 41 patients, including 12 with MYH7 variants, 14 with TTN variants and 15 with other causes of DCM. Improvements in ejection fraction were numerically largest in the genetically defined MYH7 and TTN cohorts, but the study was open-label, short and not placebo-controlled.
Ataciguat is a once-daily soluble guanylate cyclase activator being evaluated in moderate calcific aortic valve stenosis. A randomized Phase II study involving 23 treated participants reported approximately 69.8% less progression of aortic-valve calcification with ataciguat versus placebo at six months. Importantly, the difference narrowly missed conventional statistical significance in the published study, and slowing CT-measured calcification has not yet been shown to prevent valve replacement or improve survival.
Tonlamarsen is an antisense oligonucleotide targeting hepatic angiotensinogen. In the 198-patient randomized KARDINAL trial, continued monthly treatment reduced angiotensinogen substantially more than a single dose, but both groups had the same 6.7 mmHg reduction in office systolic blood pressure at week 20. The between-group difference was essentially zero, with P=0.97. Kardigan is now repositioning development toward patients after hospitalization for acute severe hypertension, with Phase II data expected in the first half of 2027.
Why it matters
- HTA bodies: Kardigan’s programmes highlight a coming assessment problem: when treatment is built around genetics, disease stage or a specific biological pathway, the value proposition may depend heavily on how precisely the eligible population is defined. HTA will need to distinguish plausible mechanistic targeting from demonstrated clinical benefit.
- Payers: Precision can narrow the treated population, but it can also add diagnostic costs. A successful genetically targeted DCM therapy, for example, could make access to genetic testing part of the reimbursement decision rather than an optional specialist investigation.
- Industry / innovation partners: Kardigan is testing three different forms of precision cardiology simultaneously. The 2027 readouts will help show whether biological selection can produce stronger development signals than conventional disease-wide programmes, or whether attractive mechanistic hypotheses still collapse when tested in larger controlled trials.
Cardiovascular medicine already stratifies patients by blood pressure, ventricular function, biomarkers, anatomy and clinical risk. Yet compared with oncology, drug development has generally been slower to divide common cardiovascular diagnoses into molecularly or genetically defined treatment populations.
Kardigan is betting that this is changing.
The company’s three lead programmes do not share a single technology. One activates cardiac myosin, another targets soluble guanylate cyclase, and the third suppresses hepatic angiotensinogen with antisense technology. What connects them is the attempt to match treatment to a more specific biological or clinical setting rather than treating cardiovascular disease as one broad therapeutic category.
Genetic DCM is the cleanest precision test
Danicamtiv is the most explicit example.
Dilated cardiomyopathy can arise from multiple causes, and pathogenic variants in genes including MYH7 and TTN can disrupt the cardiac contractile apparatus. Danicamtiv is designed to enhance cardiac myosin function, creating a biological rationale for testing whether patients with certain sarcomeric abnormalities respond differently.
That hypothesis received an early signal in the 41-patient Phase IIa study, where improvements in left ventricular ejection fraction were largest in the MYH7 and TTN cohorts. But the evidence remains preliminary. There was no placebo control, patient numbers were tiny, and the study was not designed to prove that genetic selection itself was responsible for the observed differences.
KINSHIP-DCM now has to answer the harder question: does a biologically selected population produce a reproducible clinical advantage in a randomized setting?
If it does, the implications extend beyond Kardigan. Genetic testing could move from explaining why cardiomyopathy occurred to determining which medicine a patient should receive.
Ataciguat asks whether cardiology can treat the valve before replacing it
Ataciguat represents a different form of precision.
Moderate calcific aortic stenosis is commonly monitored until disease becomes severe enough to justify valve intervention. There is currently no established pharmacological therapy proven to stop or reverse the underlying calcific valve disease.
In the earlier randomized ataciguat study, progression of CT-measured valve calcification was about 69.8% lower than with placebo, but the trial was extremely small and the primary comparison narrowly missed statistical significance. More importantly, reducing the rate of calcium accumulation is not the same as demonstrating fewer valve replacements, less heart failure or longer survival.
KATALYST-AV is now evaluating the drug in moderate disease, with an interim Phase IIb analysis expected in the first half of 2027.
This is where precision medicine runs into a familiar evidentiary problem: a more targeted mechanism does not lower the bar for proving patient benefit.
Tonlamarsen shows why mechanism alone is not enough
Tonlamarsen provides the strongest warning against overinterpreting biological precision.
The drug did exactly what its mechanism predicted in KARDINAL. Monthly administration reduced circulating angiotensinogen by 67.2% from baseline, compared with 23.0% after a single dose followed by placebo.
But blood pressure did not distinguish the groups.
Office systolic pressure fell by 6.7 mmHg in both arms, giving a between-group difference of just 0.1 mmHg and a P value of 0.97. The trial design complicates interpretation because everyone received an active dose before randomization, and the effect of that single dose persisted longer than expected. Still, the result is an important reminder that hitting a molecular target and improving a clinical endpoint are different achievements.
Kardigan is now testing tonlamarsen in the more specific setting of post-hospitalization acute severe hypertension. That may prove to be a better therapeutic niche, or it may show that narrowing the population cannot rescue an insufficient treatment effect.
That is why 2027 matters.
Kardigan has enough capital to test several carefully constructed biological hypotheses without an immediate financing crisis dictating which programme survives. Its recent IPO gives the company time, but not validation.
The next stage will show whether precision cardiology can deliver what the label promises: not simply more sophisticated patient segmentation, but measurably better treatment for the patients selected.
